Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Complaints generally focus on unclear information on subscription length and cost
The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jrgensen has agreed to appear at a Senate hearing next week to defend the pricing of the group's semaglutide-based therapies
Samra Liaquat, an experienced dental surgeon and aesthetic
Szegezdi, J., et al
,aspect=ignore)
One in five (19%) firms over 200 workers covers GLP-1 agonists for weight loss with more coverage among larger firms One-in-five (19%) firms with 200 or more workers, including 43% of firms with 5,000 or more workers, cover GLP-1 drugs for weight loss in their largest health plan in 2025
